Definitive Contract HHSN272201600036C
Award Date
8/29/16
Potential Completion Date
8/30/18
Potential Value
$444K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
PAI Life Sciences Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Seattle, WA 98102, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
11
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $441,905 firm fixed-price definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, to PAI Life Sciences Inc. for the development of a prophylactic onchocerciasis (river blindness) vaccine. The contract is designated as a total small business set-aside. PAI Life Sciences, a small disadvantaged business, will collaborate with Thomas Jefferson University and New York Blood...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $299,184 Firm Fixed Price definitive contract to PAI Life Sciences Inc., a self-certified small disadvantaged business, to develop preclinical rabbit immunogenicity data demonstrating the efficacy of a self-adjuvanting and self-amplifying ribonucleic acid (RNA) vaccine platform against human immunodeficiency virus type 1 (HIV-1). This contract was...
This federal contract award, valued at $210,507.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to PAI Life Sciences Inc., a self-certified small disadvantaged business, for the "AEROSOLIZED DELIVERY OF ANTI-TUBERCULAR DRUGS" project. The contract is a Definitive Contract with a Firm Fixed Price pricing type. PAI Life Sciences will be the prime contractor, and Research Triangle Institute (RTI International), a non-profit research organization, will...
This is a $4,937,118.00 fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, to Institut De Formulation DES Vaccins (CH) SA, a non-profit limited liability company, for the advanced development of a liposome-based saponin-containing adjuvant for use in pan-sarbecovirus vaccines. The contract has an ultimate completion date of September 29, 2028 and was awarded on September 30, 2023 with no set-aside designation...
This is a task order award under a federal contract with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The $2,910,502 cost-plus-fixed-fee contract was awarded to Leidos, Inc., a global technology and engineering company, to provide preclinical services for the development of biopharmaceutical products targeting infectious diseases. The contract has a completion date of September 19, 2021 and was awarded on...
This is a $599,234 firm fixed price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) to Celdara Medical, a small business biotechnology company, under the Small Business Innovation Research (SBIR) program. The contract is for research to discover parasite-derived tolerogenic adjuvants, which could potentially be used in new vaccine development. Celdara Medical conducts research and...
This is a $18,576,013.05 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Access To Advanced Health Institute (AAHI), a non-profit biotech research institute located in Seattle, Washington. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant infections, and emerging infectious diseases under NIAID's Broad Agency Announcement (BAA) Research Area 001. AAHI has experience as...
This is a $224,981.00 firm-fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to Epitogenesis Inc., a minority-owned, economically disadvantaged women-owned small business. The contract is for the development of "A NUTRITIVE VACCINE ADJUVANT AGAINST INFLUENZA" and has a period of performance ending on September 14, 2015. The contract was set aside for small businesses.
This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...